Huberman Lab

Podbit · Huberman Lab

Essentials: The Science & Treatment of Obsessive Compulsive Disorder (OCD)

Explore episode Jul 9, 2026

Where this was said

CBT vs Placebo vs SSRIs

At 25:30 · chapter starts 25:18

The episode's most clinically significant moment arrives in this chapter. Huberman presents the findings of Dr. Blair Simpson's landmark comparison study pitting exposure-based CBT against SSRIs and placebo. Placebo produced no meaningful reduction in OCD symptoms. SSRIs produced a significant but modest improvement. CBT, however, was transformative: Y-BOCS scores dropped from approximately 25 all the way down to about 11 within just four weeks — a nearly 60% reduction in symptom severity. When SSRIs and CBT were combined, the results were almost identical to CBT alone. There was no synergistic benefit from the combination. This finding has direct clinical implications: for patients already on SSRIs, adding CBT is the priority; for patients considering treatment, CBT alone may be sufficient and may be the more powerful starting point.

Similar podbits

Health & Fitness
AI in Healthcare: Where It Helps and Where It Doesn't

Using AI to Increase Your Intelligence & Enrich Humanity | … · Aug 10, 2026 Health & Fitness

AI nailed Andrew Huberman's vertigo-vs-low-blood-pressure diagnosis because that pattern has been reported millions of times. But every patient's liver is different and data on liver surgeries is scarce worldwide — making solo robot surgery dangerous. The rule is simple: data abundance means AI can help; data scarcity means keep the human in the loop.